Primary hyperparathyroidism (PHPT) is a common endocrine disorder which occurs most frequently in post-menopausal women and is characterized by mild, stable, and often asymptomatic hypercalcaemia. Chronic parathyroid hormone excess stimulates bone remodelling by inducing production by osteoblasts of soluble factors which stimulate both bone formation and osteoclastic bone resorption. Studies of bone mineral density (BMD) in PHPT suggest that bone loss is accelerated, leading to osteopenia, particularly at sites of cortical bone. Studies of fracture incidence in PHPT have produced conflicting results. Interventional studies have demonstrated that both parathyroid adenomectomy and estrogen replacement therapy increase BMD in patients with PHPT. Patients with PHPT should undergo BMD measurement, and receive treatment designed to stabilize bone mass if there is evidence of either osteopenia or accelerated bone loss.
No takes yet. Share an insight, caveat, or question.
Andrew Grey (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: